Drugs / CD45RA depleted donor lymphocyte infusion (DLI)
CD45RA depleted donor lymphocyte infusion (DLI)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07662369 | Jun 2026 → Jun 2027 expected | hematopoietic and lymphoid cell neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD45RA depleted donor lymphocyte infusion (DLI) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662369 ↗ |
| Modality | Cell therapy | “special donor immune cells (called "CD45RA Depleted DLI")” NCT07662369 ↗ |